A PYMNTS Company

US/EU: Monsanto mulled merger to relocate taxes

 |  June 24, 2014

According to reports released this week, agricultural biotech giant Monsanto was considering an acquisition of a Switzerland-based rival in hopes of transferring its tax location outside the US.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say Monsanto explored a buyout of Syngenta for more than $40 billion. Syngenta reportedly declined to pursue negotiations, however, and the merger never consummated.

    But Monsanto’s plans are part of a growing trend of other major corporations hoping to lessen their tax burden through EU acquisitions. Reports say Pfizer, AstraZeneca and AbbVie have all looked at ways to save money through tax inversion by moving their address outside the US. Medtronic recently announced it will save up to $14 billion by doing so.

    Reports say relocation difficulties and likely antitrust hurdles stymied merger talks between Monsanto and Syngenta.

    The European Commission is currently probing the tax policies of several EU member states and their relationships to major non-EU companies for possible anticompetitive consequences.

    Full content: Benzinga

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.